Nightfood Holdings Inc. (OTCQB: NGTF) announced that its subsidiary, TechForce Robotics, has successfully completed Phase 1 objectives under its joint development agreement with Oncotelic Therapeutics (OTCQB: OTLC), highlighted by the initial deployment of LIM-E, an autonomous laboratory support robot. The deployment marks TechForce's first expansion into pharmaceutical and laboratory automation and validates the adaptability of its AI-enhanced robotics platform beyond hospitality and service-industry applications into life sciences and pharmaceutical environments.
TechForce said the deployment completed the initial operational goals established under the companies' April 2026 collaboration agreement and will provide operational data and workflow insights to support future automation initiatives. The companies plan to continue evaluating opportunities in laboratory logistics, manufacturing support, AI-enhanced workflows and other automation applications, while Nightfood views healthcare, life sciences and pharmaceutical manufacturing as significant long-term growth markets for its Robotics-as-a-Service platform.
For more information, see the full press release at https://ibn.fm/RFkfL.
